effects were small, he said. "This treatment is simple, it is inexpensive, it can be used in rich and poor countries, it can be used in big and small hospitals," Yusuf said. The finding may also show doctors that the drugs called low-molecular-weight heparins, which help prevent the blood from clotting, might be a good addition to aspirin and other drugs that heart patients typically get, he said. Yusuf believes his findings will translate globally. "Every risk factor behaves identically in every ethnic group in the world," he said. The trial is part of a larger study that is looking at 20,000 patients in 21 regions, including India, Pakistan, China, Argentina, Chile, Brazil, Venezuela as well as countries in Europe and the Middle East. The study was sponsored by a group of academic centers and did not involve a commercial sponsor. --SP 0002 Local Time 2102 GMT
